About
Silver medal won at research and innovation exhibition organized by UPM, Malaysia.
Parham Jabbarzadeh Kaboli
Dr. Parham Jabbarzadeh Kaboli, with an h-Index of 22, is a passionate researcher focusing on cancer pharmacology, pharmacogenomics, and drug discovery. His academic path commenced with a firm grounding in herbal medicine, culminating in successfully attaining his Ph.D. in Pharmacology (2013-2018) from the University Putra Malaysia (among the top 200 world universities in the QS system). Throughout this academic journey, Parham actively engaged in pioneering research to advance targeted therapies for breast cancer. This groundbreaking work was conducted under the guidance and mentorship of Associate Professor Dr. King-Hwa Ling. Dr. Ling, a distinguished figure in the fields of neuroscience and medical genetics, has been a pivotal mentor and a catalyst in initiating Parham's academic journey.
During his Ph.D. studies, Professor Johnson Stanslas was pivotal in mentoring Parham in the intricate realm of pharmacology. His guidance and insights were instrumental in shaping Parham's academic trajectory. Under Professor Stanslas' mentorship, Parham found the inspiration and direction to transition from his initial focus on Molecular Medicine to the multifaceted disciplines of Pharmacology and Toxicology. This transition opened new horizons for Parham, allowing him to delve deeper into the intricate world of drug interactions, mechanisms, and the study of toxic agents. Professor Stanslas' mentorship was transformative and marked a significant turning point in Parham's academic journey, setting the stage for his subsequent accomplishments in the field.
After completing his Ph.D. in 2018, he became a lecturer and full-time faculty member in the Department of Pharmacology at the School of Pharmacy, Southwest Medical University in China (2019-2021). Working closely with Emeritus Prof. Chi-Hin Cho and Prof. Zhangang Xiao, he delved into the complexities of targeted therapies, paving the way for innovative approaches to combat this devastating disease.
Parham's steadfast devotion to cancer research is brilliantly evident in his academic journey and investigative undertakings. His initial ventures into herbal medicine and biology provided a solid foundation upon which he immersed himself in the field of pharmacology. Parham has continued to enhance his capacity for developing advanced ideas in the realm of cancer research, particularly during his tenure as a postdoctoral research fellow specializing in cancer biology (2021-present).
Since 2021, he has been under the mentorship of President Mien-Chie Hung at China Medical University, where he continues to make noteworthy contributions.
Professor Mien-Chie Hung is an eminent figure in molecular biology and cancer research, distinguished for his remarkable h-Index of 170 and an impressive citation count exceeding 100,000. He previously held the esteemed position of Professor and Chair in the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. Professor Hung's scientific odyssey began in 1984 when he embarked on a transformative journey at the Massachusetts Institute of Technology, where he had the privilege of working under the esteemed guidance of renowned molecular biologist Dr. Robert A. Weinberg. In 2019, Professor Hung took on the prestigious mantle of President at China Medical University in Taichung, Taiwan.
Parham's collaboration with Professor Hung exemplifies his exceptional capacity to participate actively and significantly contribute to cutting-edge research in breast cancer treatment. This partnership is driven by Parham's robust educational background and an unwavering enthusiasm for exploration and innovation.
Parham's remarkable accomplishments within the field have been attained through a journey that has taken him across three different countries, diverse laboratory environments, and fruitful collaborations with respected mentors and leaders. These achievements include discovering novel signaling pathways related to the c-MET receptor tyrosine kinase and galectin-9, specifically in targeted therapy and immunotherapy for breast cancer.
Research Impact
Testimonials
